US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.
Results and Decision Basis
The decision was based on promising results from primate studies, which demonstrated that Capsida’s engineered adeno-associated virus (AAV) capsids can effectively deliver AbbVie’s novel therapeutic cargo intravenously (IV). This capability highlights the potential of Capsida’s technology to advance treatments for neurodegenerative diseases.
Roles and Responsibilities
AbbVie will be responsible for advancing the program into IND-enabling studies and conducting clinical trials, while Capsida will take charge of manufacturing. This division of responsibilities leverages the strengths of both companies to accelerate the development of innovative therapies for neurodegenerative diseases.
Significance of the Collaboration
This milestone underscores the ongoing collaboration between Capsida Biotherapeutics and AbbVie, highlighting their shared commitment to advancing cutting-edge treatments for neurodegenerative conditions. The partnership is poised to drive significant progress in the development of therapies that could improve patient outcomes in this critical area.-Fineline Info & Tech
